Human Rhinovirus (HRV) is reported to be a leading cause of up to 80% of asthma exacerbations. The viral pathway and associated immune responses represent a potential key therapeutic target for new and novel asthma treatments. The use of a human viral challenge model has been widely explored over the last few decades and there is interest in its use to enhance early clinical development.
